

# FRANCES E. BROYLES, MD

800 SW 39th St, Ste 110, Renton, WA · 425-251-1720 (Office) FBroyles@Rainier-Research.com

Founded in 1991, Rainier Clinical Research Center is a private, dedicated, multi-specialty investigative site conducting Phase I-IV clinical trials for drugs and devices. We have successfully completed 600+ studies with 200+ sponsors and contract research organizations.

#### **EXPERIENCE**

JUL 2022 - PRESENT

MEDICAL DIRECTOR, RAINIER CRC, LLC

2019 TO JUL 2022

MEMBER OF PROVIDENCE HEALTHCARE DIABETES FOCUS GROUP OVER INPATIENT INSULIN **ORDER SETS** 

2018 TO JUL 2022

CHAIR/CLINICAL LEAD "HEALTHY WEIGHT INITIATIVE PROVIDENCE HEALTHCARE SYSTEM 2017 TO JUL 2022

ADA BOARD MEMBER WASHINGTON

2017 TO JUL 2022

ENDOCRINOLOGY LEAD DIGESTIVE HEALTH INSTITUTE, SWEDISH HEALTH CARE SYSTEMS 2015 TO JUL 2022

CLINICAL MEDICAL DIRECTOR OVER THE OUTPATIENT DIABETES EDUCATION PROGRAM,

**SWEDISH** 

2015 TO JUL 2022

CHAIR/CLINICAL LEAD "DIABETES PATHWAY, SWEDISH /PROVIDENCE HEALTHCARE SYSTEMS

2015-JUL 2022

MEDICAL DIRECTOR OF ENDOCRINOLOGY / DIABETES / NUTRITION INPATIENT AND OUTPATIENT,

SWEDISH HEALTHCARE SYSTEM SWEDISH HEALTH CARE SYSTEMS, WA

2015 TO JUL 2022

CHAIR INPATIENT GLYCEMIC TEAM, SWEDISH HEALTH CARE SYSTEMS

2015 TO JUL 2022

CLINICAL MEDICAL DIRECTOR OVER THE INPATIENT GLYCEMIC TEAM, SWEDISH HEALTH CARE

SYSTEM

JUL 2022

PROCTOR AND GAMBLE NATIONAL OSTEOPOROSIS CONSULTING BOARD

MEDICAL DIRECTOR OF NEUROENDOCRINOLOGY INSTITUTE SWEDISH NEUROSCIENCE INSTITUTE, SWEDISH MEDICAL CENTER, SEATTLE, WA

Signature: Fra Burgles

Date: 7/6/2022

CV BroylesFrances Page 1 of 8



2011-JUL 2022

**CLINICAL ENDOCRINOLOGIST, SWEDISH MEDICAL GROUP** 

1992-1993

ENDOCRINOLOGY, SUMMIT MADISON MEDICAL GROUP, SEATTLE, WA

1993-2009

ENDOCRINOLOGY, MINOR AND JAMES MEDICAL, PLLC, SEATTLE, WA

2009-2011

ENDOCRINOLOGY, QLIANCE MEDICAL GROUP, SEATTLE, WA

1986-1987

DIRECTOR CARDIAC REHAB PROGRAM, THE COOPER CLINIC PREVENTATIVE MEDICINE CLINIC,

**DALLAS TEXAS** 

1986-1987

MEDICAL DIRECTOR THE "IN RESIDENCE "PREVENTATIVE MEDICINE PROGRAM, THE COOPER

CLINIC PREVENTATIVE MEDICINE CLINIC, DALLAS TEXAS

1974-1981

PRINCIPAL DANCER AND SOLOIST, GAINESVILLE CIVIC BALLET AND DANCE ALIVE PROFESSIONAL

COMPANY

**HEALTH CARE SYSTEM** 

## **EDUCATION**

1977-1980

BACHELOR SCIENCE, INTERDISCIPLINARY BIOLOGICAL MEDICINE, UNIVERSITY OF FLORIDA,

GAINESVILLE, FL

#### POSTGRADUATE TRAINING

1990-1992

SENIOR FELLOW, DIVISION OF ENDOCRINOLOGY AND METABOLISM, UNIVERSITY OF

WASHINGTON, SEATTLE, WA

1989-1990

CHIEF RESIDENT, INTERNAL MEDICINE, PRESBYTERIAN HOSPITAL, DALLAS, TX

1987-1989

INTERNAL MEDICINE, PRESBYTERIAN HOSPITAL, DALLAS, TX

1984-1985

INTERNAL MEDICINE, ALBANY MEDICAL CENTER, ALBANY, NY

1980-1984

MEDICAL DOCTORATE, UNIVERSITY OF FLORIDA, GAINESVILLE, FL



## **BOARD CERTIFICATIONS**

1989

AMERICAN BOARD OF INTERNAL MEDICINE

1983, 2017

AMERICAN BOARD OF ENDOCRINOLOGY AND METBOLISM

#### LICENSURE TO PRACTICE

1990 - JUL 2022

STATE OF WASHINGTON (MD00027695)

#### **FACULTY POSITIONS**

1992-JUL 2022

ASSOCIATE CLINICAL PROFESSOR, CLINICAL DEPARTMENT OF METABOLISM AND ENDOCRINOLOGY FACULTY, SCHOOL OF MEDICINE, UNIVERSITY OF WASHINGTON, SEATTLE, WA.

## **PROFESSIONAL AFFILIATIONS**

AMERICAN COLLEGE OF PHYSICIANS

KING COUNTY MEDICAL SOCIETY

WASHINGTON STATE MEDICAL ASSOCIATION

JUNIOR ALPHA OMEGA ALPHA 1983

**OUTSTANDING WOMEN IN MEDICINE 1984** 

MEMBER OF ADA

MEMBER OF ENDOCRINE SOCIETY

MEMBER OF AACE

MEMBER OF OMA

# **AWARDS**

1984 TO 2021



TOP DOCTOR SEATTLE MAGAZINE AND/OR SEATTLE METROPOLITAN MAGAZINE YEARLY

YEARLY

1984

**OUTSTANDING WOMEN IN MEDICINE** 

1983

JUNIOR AOA

1980

PHI BETA KAPPA

1980

JUNIOR HONORS EARLY ACCEPTANCE TO MEDICAL SCHOOL PROGRAM/BS AND MD IN 7 YEARS

1977

TOP MATHEMATICS AWARD

1977

BAUSCH AND LOMB SCIENCE AWARD

1971

DANCE SCHOLARSHIP NEW YORK CITY

#### **PROJECTS**

2022

DEVELOPMENT AND IMPLEMENTATION OF VIRTUAL CONSULT CAPABILITY OF INPT DM EDUCATION SWEDISH HEALTH CARE SYSTEM

2022

ENDOCRINOLOGY LEAD FOR PMG/SMG HEALTH EQUITY PROJECT AROUND IMPROVING DM AND OBESITY CARE IN UNDERSERVED POPULATIONS AND MARGINALIZED POPULATIONS 2022

DEVELOPMENT OF PATHWAY FOR RAPID DISCHARGE CAPTURE OF DM PTS AT HIGH RISK FOR MORBIDITY/MORTALITY, RE ADMIT, ER VISITS, AND INCREASED LOS

2021 TO JUL 2022

STANDARDIZATION OF TRAD CLASSIFICATION OF SWEDISH RADIOLOGY REPORTS OF THYROID NODULES ENDOCRINOLOGY LEAD ON LGBTQ/TRANSGENDER TREATMENT PROTOCOLS 2021 TO JUL 2022

PROGRAM COLLABORATION WITH CARDIOLOGY AND OBESITY MEDICINE AT SMG FOR TREATMENT OF OBESITY AND ATRIAL FIBRILLATION

2021

COLLABORATION WITH DR. KRIS KOWDLEY ON A PROTOCOL FOR THE TREATMENT OF NASH IN DIABETES AND OBESITY

2020 TO JUL 2022

DEVELOPMENT AND IMPLEMENTATION OF CLOUD BASED CAPTURE OF CGMS, INSULIN PUMPS AND INSULIN METERS FOR SWEDISH ENDOCRINOLOGY PROVIDERS

2020 TO JUL 2022

DEVELOPMENT AND IMPLEMENTATION OF OUTPT TELEHEALTH VISITS, BILLING, AND TEMPLATES FOR ENDOCRINOLOGY AND PROVIDERS AND DM EDUCATION

2020 TO JUL 2022

DEVELOPMENT AND IMPLEMENTATION OF TELEHEALTH DM OUTPT EDUCATION CLASSES



2020 TO JUL 2022

ENDOCRINOLOGY MEMBER OF DM INPT INSULIN ORDER SETS FOR PROVIDENCE HEALTHCARE SYSTEM

2020 TO JUL 2022

DEVELOPMENT OF PARTNERSHIP WITH PROVIDENCE CREDENA PHARMACY FOR COVERAGE OF OBESITY AND DIABETES MEDICATIONS

2020

DEVELOPMENT OF PROTOCOL WITH ANESTHESIA ON THE PERI OP MANAGEMENT AND PREPARATION FOR PHEOCHROMOCYTOMA

2019 TO JUL 2022

ENDOCRINOLOGY LEAD ON 360 POPULATION DASHBOARD DEVELOPMENT TO TRACK OBESITY/COMORBIDITIES AND INTERVENTIONS SMG AND PMG

2019 TO JUL 2022

ENDOCRINOLOGY LEAD/CONSULTANT ON PROVIDENCE HMR (HEALTHY MEAL REPLACEMENT)
2019

**DPP TRAINING AND ROLL OUT** 

2018 TO JUL 2022

CLINICAL LEAD HEALTHY WEIGHT INITIATIVE/STANDARDS OF CARE FOR OBESITY TREATMENT. SWEDISH/PROVIDENCE HEALTHCARE SYSTEM

2018

DEVELOPMENT OF DM EDUCATIONAL VIDEOS FOR SMART PHONE USE G2L PROJECT 2017 TO JUL 2022

PARTNERSHIP AND PATHWAY WITH THE YMCA FOR SMG REFERRAL TO DPP AND LOSE TO WIN PROGRAMS

2017 TO 2019

ENDOCRINOLOGY LEAD/CONSULTANT FOR THE GLOBAL TO LOCAL PROJECT, A PROJECT TO DEMONSTRATE THE EFFECTIVENESS OF GLOBAL HEALTH STRATEGIES, TECHNIQUES, METHODOLOGIES, AND TECHNOLOGIES TO IMPROVE THE HEALTH STATUS OF LOCAL UNDERSERVED COMMUNITIES IN SOUTH KING COUNTY

2017 TO 2019

PARTNERSHIP WITH WEIGHT WATCHERS AND SMG

2016 TO JUL 2022

WOMEN'S AND INFANTS POST-PARTUM DM MOTHER AND BABY CAPTURE AND EDUCATION WITH AN AIM TOWARD PREVENTION AND EDUCATION

2016

BALLARD HIGH SCHOOL TEEN PILOT STUDY TARGETING BEHAVIORAL CHANGE WITH TEXT MESSAGING TO ADDRESS OBESITY AND DM RISK

2015 TO JUL 2022

CLINICAL LEAD DIABETES PATHWAY BUILD/STANDARDS OF CARE SWEDISH/PROVIDENCE HEALTH CARE SYSTEM

2015 TO JUL 2022

DEVELOPMENT AND REPORTING OF DM METRICS/BUNDLE SMG AND PMG

2015 TO JUL 2022

ENDOCRINOLOGY LEAD ON DEVELOPMENT AND STANDARDIZATION OF INPATIENT INSULIN ORDER SETS SWEDISH HEALTHCARE SYSTEM



2015 TO JUL 2022

DEVELOPMENT AND OVERSIGHT OF THE INPATIENT GLYCEMIC TEAM, EXAMINING ALL PT CHARTS IN HOUSE (5 CAMPUSES) WITH BLOOD SUGARS >180 OR < 70 WITH TARGETED INTERVENTION EDUCATION OF INPATIENT NURSING STAFF ON INPT INSULIN PROTOCOLS 2015 TO JUL 2022

PROJECTS PARTNERING WITH ADA

2015 TO JUL 2022

EDUCATION OF INPT PROVIDERS, HOSPITALISTS, RESIDENTS, SURGEONS, AND ANESTHESIOLOGISTS, ON INPT INSULIN ORDER SETS, WITH CONTINUED EDUCATIONAL SUPPORT 2015 TO JUL 2022

DIABETES EDUCATION OF CRUISE LINE EMPLOYEES DOCKING IN SEATTLE 1990'S

DEVELOPMENT OF THE OSTEOPOROSIS CENTER MINOR AND JAMES MEDICAL

## RESEARCH PROJECTS

VLDL TURNOVER STUDIES EXAMINING AFFECTS OF HMG COA INHIBITION IN DIABETICS MELLITUS AND HYPERLIPIDEMIA.

VLDL/IDL TURNOVER STUDIES IN TYPE III HYPERLIPIDEMIA

EFFECTS OF STRESS ON LIPIDS USING PSYCHOLOGICAL STRESSORS AND EPINEPHRINE INFUSIONS

EFFECTS OF DIFFERENT ORAL CONTRACEPTIVES ON HDL: SUBCLASSES AND LIPOPROTEINS.

**EFFECT OF FLUVASTATIN ON REMNANT LEVELS** 

A THREE CENTER, DOSE ESCALATING, RANDOMIZED, DOUBLE BLIND STUDY OF THE SAFETY AND EFFICACY OF A NEW NIACIN FORMULATION IN COMPARISON WITH PLACEBO IN PATIENTS WITH ELEVATED CHOLESTEROL.

A RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE SAFETY AND EFFICACY OF DIFFERENT DOSE LEVELS OF PASIREOTIDE (SOM230) S.C. OVER A 6 MONTH TREATMENT PERIOD IN PATIENTS WITH DE NOVO, PERSISTENT OR RECURRENT CUSHING'S DISEASE, PRINICIPAL INVESTIGATOR

NON-INTERVENTIONAL STUDY FOR THE GENERATION OF LONG-TERM SAFETY AND EFFICACY DATA OF PASIREOTIDE S.C. IN PATIENTS WITH CUSHING'S DISEASE (POST-AUTHORIZATION SAFETY STUDY), PRINICIPAL INVESTIGATOR

AN OPEN LABEL, MULTICENTER, SINGLE-ARM STUDY OF PASIREOTIDE LAR IN PATIENTS WITH RARE TUMORS OF NEUROENDOCRINE ORIGIN, PRINICIPAL INVESTIGATOR

A MULTICENTER, RANDOMIZED, BLINDED STUDY TO ASSESS SAFETY AND EFFICACY OF PASIREOTIDE LAR VS. OCTREOTIDE LAR IN PATIENTS WITH ACTIVE ACROMEGALY, PRINICIPAL INVESTIGATOR



ASSESSING THE MINIMAL IMPORTANT DIFFERENCE (MID) OF THE TREATMENT RELATED IMPACT MEASURE—ADULT GROWTH HORMONE DEFICIENCY (TRIM-AGHD) A PROSPECTIVE NON-INTERVENTIONAL STUDY, PRINICIPAL INVESTIGATOR

A PHASE 3, MULTICENTER STUDY DESIGNED TO EVALUATE THE EFFICACY AND SAFETY OF A LONG ACTING HGH PRODUCT (MOD-4023) IN ADULT SUBJECTS WITH GROWTH HORMONE DEFICIENCY, PRINICIPAL INVESTIGATOR

AN ACROMEGALY, OPEN-LABEL, MULTI-CENTER SAFETY MONITORING PROGRAM FOR TREATING PATIENTS WITH SOM230 (PASIREOTIDE) LAR WHO HAVE NEED TO RECEIVE MEDICAL THERAPY (ACCESS), PRINICIPAL INVESTIGATOR

## **PRESENTATIONS**

DIABETES SWEDISH SYSTEM CME

**NEUROENDOCRINE CME** 

PRE-DIABETES AND DIABETES PREVENTION

PARADIGM SHIFT IN THE TREATMENT OF TYPE 2 DM

FATTY LIVER A CALL TO ACTION- HEMATOLOGY

THE RATIONALE OF INPATIENT GLYCEMIC CONTROL

**OVERVIEW OF THE PITUITARY** 

**EVALUATION OF POST OP PITUITARY FUNCTION** 

PHARMACOTHERAPY OF OBESITY

THE USE OF MEAL REPLACEMENTS AS PART OF THE TREATMENT OF OBESITY

OVERVIEW OF SGLT2 AND GLP1 MEDICATIONS AND INDICATIONS FOR USE WITH RESPECT TO CVD AND RENAL DZ

THE TREATMENT APPROACH TO THE EPIDEMIC OF OBESITY

MANAGEMENT OF INSULIN AND GLUCOSE CONTROL PERIOPERATIVELY IN BARIATRIC SURGERY

RATIONALE FOR TIGHT GLUCOSE CONTROL PERI OPERATIVELY

**ORAL HEALTH AND DIABETES** 

ADA DM STANDARDS OF CARE YEARLY

TREATMENT AND PREVENTION OF OSTEOPOROSIS



## **BIBLIOGRAPHY**

Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH: Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol, 1995; 76(1): 129A-135A. PMID: 7604788.

Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, Kivel F, Black DM. Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined with Colestipol. J Cardiovasc Pharmacol Ther. 1996 Apr;1(2):117-122. doi: 10.1177/107424849600100205. PMID: 10684408.

Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception. 2001 Jan;63(1):1-11. doi: 10.1016/s0010-7824(00)00196-7. PMID: 11257242.

Knopp RH, Frohlich J, Jokubaitis LA, Dawson K, Broyles FE, Gomez-Coronado D. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med. 1994 Jun 6;96(6A):69S-78S. doi: 10.1016/0002-9343(94)90235-6. PMID: 8017470.

Knopp RH, Illingworth DR, Stein EA, Ginsberg HN, Broyles FE, Behounek BD: Effect of pravastatin in the treatment of patients with type III hyperlipoproteinemia. Am J Ther, 1996 Nov; 3(11): 755-762. PMID: 11862234.

Mayberg M, Reintjes S, Patel A, Moloney K, Mercado J, Carlson A, Scanlan J, Broyles F. Dynamics of postoperative serum cortisol after transsphenoidal surgery for Cushing's disease: implications for immediate reoperation and remission. J Neurosurg. 2018 Nov 1;129(5):1268-1277. doi: 10.3171/2017.6.JNS17635. PMID: 29271716.

McCann BS, Magee MS, Broyles FE, Vaughan M, Albers JJ, Knopp RH: Acute psychological stress and epinephrine infusion in normolipidemic and hyperlipidemic men: effects on plasma lipid and apoprotein concentrations. Psychosom Med, 1995; 57(2): 165-176. PMID: 7792375.

Moisi M, Cruz AS, Benkers T, Rostad S, Broyles FB, Yuen K, Mayberg M. Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review. Cureus. 2016 Jun 27;8(6):e658. doi: 10.7759/cureus.658. PMID: 27489751; PMCID: PMC4963231.

Moloney KJ, Mercado JU, Ludlam WH, Broyles FE. Diagnosis of Cushing's disease in a patient with consistently normal urinary free cortisol levels: a case report. Clin Case Rep. 2016 Nov 9;4(12):1181-1183. doi: 10.1002/ccr3.647. PMID: 27980758; PMCID: PMC5134332.